Search Results - "Vaena, D"

Response to anti-DKK1 therapy in uterine carcinosarcoma: A case report by ElNaggar, A., Zhang, N., Scalise, C.B., Sirard, C., Kagey, M.H., Vaena, D., Arend, R.

“…•Targeted therapies are being increasingly used in clinical practice and trials.•Tumor heterogeneity among sites of metastasis create a conundrum when…”
Get full text

Efficacy of cabozantinib vs everolimus in advanced renal cell carcinoma with bone metastases: results from the phase 3 METEOR study by Bracarda, S, Choueiri, T.K, Powles, T, Motzer, R.J, Olencki, T, Frontera, O.A, Oudard, S, Rolland, F, Tomczak, P, Castellano, D, Appleman, L, Drabkin, H, Vaena, D, Milwee, S, Youkstetter, J, Escudier, B

Get full text

1881O Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study by Agarwal, N., Brugarolas, J., Ghatalia, P., George, S., Haanen, J.B.A.G., Gurney, H.P., Ravilla, R., Van der Veldt, A.A.M., Beuselinck, B., Pokataev, I., Suelmann, B.B., Tuthill, M., Vaena, D., Zagouri, F., Wu, J., Liu, Y., Perini, R., Merchan, J.R., Atkins, M.B.

Get full text

Long-Term Survival After High-Dose Salvage Chemotherapy for Germ Cell Malignancies With Adverse Prognostic Variables by VAENA, Daniel A, ABONOUR, Rafat, EINHORN, Lawrence H

“…Independent prognostic variables for patients undergoing high-dose chemotherapy (HDCT) as salvage modality for germ cell tumors (GCT) were previously…”
Get full text

917PClinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22 by Siefker-Radtke, A O, Lugowska, I, Tupikowski, K, Andric, Z G, Rezazadeh Kalebasty, A, Curigliano, G, Vaena, D, Vogl, F D, Currie, G, Abella, S, Kelly, W

“…Abstract Background Patients (pts) with mUC who have failed platinum-based chemotherapy have a poor prognosis. Reported response rates to immune checkpoint…”
Get full text

Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22 by Siefker-Radtke, A.O., Lugowska, I., Tupikowski, K., Andric, Z.G., Rezazadeh Kalebasty, A., Curigliano, G., Vaena, D., Vogl, F.D., Currie, G., Abella, S., Kelly, W.

Get full text

917P - Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22 by Siefker-Radtke, A.O., Lugowska, I., Tupikowski, K., Andric, Z.G., Rezazadeh Kalebasty, A., Curigliano, G., Vaena, D., Vogl, F.D., Currie, G., Abella, S., Kelly, W.

“…Patients (pts) with mUC who have failed platinum-based chemotherapy have a poor prognosis. Reported response rates to immune checkpoint inhibitors (ICI) are…”
Get full text

Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study by Galsky, M.D., Retz, M., Siefker-Radtke, A.O., Baron, A., Necchi, A., Bedke, J., Plimack, E.R., Vaena, D., Grimm, M.-O., Bracarda, S., Arija, J. Arranz, Pal, S.K., Ohyama, C., Saci, A., Lambert, A., Krishnan, S., Azrilevich, A., Sharma, P.

Get full text

159P COM701 in combination with nivolumab demonstrates preliminary antitumor activity in patients with platinum-resistant epithelial ovarian cancer by Yeku, O., D. Shepard, Patel, M., Fleming, G., Vaena, D., Rasco, D., Chmielowski, B., Sharma, M.R., Hamilton, E., Sullivan, R.J., Papadopoulos, K., Izar, B., Cojocaru, G., Ophir, E., Ferre, P.J., Dumbrava, E.E.

Get full text

158P Triple blockade of the DNAM-axis with COM701 + BMS-986207 + nivolumab demonstrates preliminary antitumor activity in patients with platinum-resistant OVCA by Moroney, J., Yeku, O., Fleming, G., Emens, L.A., Vaena, D., Dumbrava, E.E., Rasco, D., Sharma, M.R., Papadopoulos, K., Patnaik, A., Sullivan, R.J., Adewoye, H.H., Ophir, E., Cojocaru, G., Ferre, P.J., Izar, B., Gaillard, S.

Get full text

130P COM701 ± nivolumab: Preliminary results of antitumor activity from a phase I study in patients with metastatic NSCLC who have received prior PD-1/PD-L1 inhibitor by Sullivan, R.J., Sharma, M.R., Vaena, D., Hamilton, E., Izar, B., Rasco, D., Gainor, J., D. Shepard, Papadopoulos, K., Dumbrava, E.E., Adewoye, H.H., Ferre, P.J., Ophir, E., Patel, M., Patnaik, A., Chmielowski, B.

Get full text

2196 - Efficacy of cabozantinib vs everolimus in advanced renal cell carcinoma with bone metastases: results from the phase 3 METEOR study by Bracarda, S., Choueiri, T.K., Powles, T., Motzer, R.J., Olencki, T., Frontera, O.A., Oudard, S., Rolland, F., Tomczak, P., Castellano, D., Appleman, L., Drabkin, H., Vaena, D., Milwee, S., Youkstetter, J., Escudier, B.

Get full text

Lymph node density and number of adjuvant chemotherapy cycles for node-positive resected bladder cancer: University of Iowa experience by Abu Hejleh, T., O'Donnell, M., Vaena, D.

“…Abstract only e16126 Background: Although its survival benefit is unclear, adjuvant chemotherapy (CT) is commonly utilized for node-positive bladder cancer…”
Get full text

A25 LUNG INJURY: MARKERS AND OUTCOMES: Sonographic B-Lines Correlate With Plasma Angiopoietin-2 During Early Acute Lung Injury Induced By Clinical Interleukin-2 Therapy by Gores, K, Delsing, A, Monick, M M, Gehlbach, B K, Schmidt, G A, Durairaj, L, Vaena, D, Milhem, M, Gerke, A K, Zabner, J, Doerschug, K

Get full text

Genetic variability in DNA repair and clinical outcome in stage III non-small cell lung cancer (NSCLC) treated with concurrent platinum-based chemoradiation by Al Omari, A., Murry, D. J., Smith, B. J., Clamon, G., Bhatia, S., Vaena, D.

“…Abstract only e14621 Background: Concurrent platinum-based chemoradiation (CRT) is the standard of care for stage III NSCLC. CRT is associated with multiple…”
Get full text

Radiolabeled anti-prostate specific membrane antigen (PSMA) monoclonal antibody J591 ( 177 Lu-J591) for nonmetastatic castration-resistant prostate cancer (CRPC): A randomized phase II trial by Tagawa, S. T., Hahn, N. M., Vaena, D. A., Quinn, D. I., Kelly, W. K., Christos, P. J., Osborne, J., Vallabhajosula, S., Nadeau, K., Mileo, G., Tyrell, L., Saran, A., Ecker, C., Beltran, H., Goldsmith, S. J., Nanus, D. M.

“…Abstract only…”
Get full text

Correlation of statin use and duration with increased survival in hormone refractory prostate cancer by Rich, N. T., Smith, B. J., Vaena, D. A.

“…Abstract only 14617 Background: Prior studies associated statin use with prevention and reduced progression of prostate cancer. (Platz et al, 96 th AACR abst…”
Get full text

Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206 by Rini, B. I., Halabi, S., Rosenberg, J., Stadler, W. M., Vaena, D. A., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., Small, E. J.

“…Abstract only…”
Get full text

Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206 by Rini, B. I., Halabi, S., Rosenberg, J., Stadler, W. M., Vaena, D. A., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., Small, E. J.

“…Abstract only LBA5019 Background: Bevacizumab (BEV) plus interferon alpha (IFN) demonstrated a superior objective response rate and progression-free survival…”
Get full text

A phase II trial of an adenovirus/PSA vaccine for prostate cancer by Lubaroff, D. M., Vaena, D. A., Williams, R. D., Joudi, F. N., Smith, M. C., Zehr, P. S., Eastman, J., Griffith, K., Madsen, T. M., Johnson, K.

“…Abstract only 3065 Background: Our phase I adenovirus/PSA vaccine trial has proven the vaccine is safe. We are conducting a phase II clinical trial with two…”
Get full text